Russia Oncology Drugs Market Analysis Report 2022 to 2030

Russia Oncology Drugs Market Analysis

$ 3999

Russia's Oncology Drugs Market size was valued at $xx Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of xx% from 2022-30 and will reach $xx Bn in 2030. The rising oncology burden in Russia owing to the increased consumption of alcohol and tobacco is driving the growth of the global oncology market. The market is segmented by Drug Class, Therapy, Indication, Dosage Form, and Distribution Channel. The major companies in Russia's Oncology Drugs Market are Roche, Bristol-Myers Squibb, Veropharm (Abbott), MSD, Sanofi, Novartis, and others.

ID: IN10RUPH018 CATEGORY: Pharmaceuticals GEOGRAPHY: Russia AUTHOR: Chandani Patel

Buy Now

Russia Oncology Drugs Market Executive Summary

Russia's Oncology Drugs Market size was valued at $xx Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of xx% from 2022-30 and will reach $xx Bn in 2030. Over the past few years, Russia has spent an average of 5% of its GDP on healthcare, which is less than OECD nations, which spend close to 10% of their GDP on healthcare (Macrotrends, 2021). Russia’s Annual Household Income per Capita reached $6.52 Bn in Dec 2021, compared with the previous value of $6.031 In Dec 2020. Russia’s Annual Household Income per Capita data is updated yearly, available from Dec 1992 to Dec 2021, with an average value of $5 Bn.

In Russia, the accumulated risk of developing cancer by the age of 75 was 24.7% (29.4% were men and 22.3% – were women). By the end of 2014, registered cancer care facilities were 3.29 Mn patients which is responsible for this phenomenon and consequently leading to the growth of the market. There are annually about 2 Mn cancer patients in need of palliative care that is inaccessible (for drug-related regulatory reasons) for a great number of patients. In terms of five-year the survival rate, in 2014 only 52.4% of cancer patients could overcome the five-year period after first being diagnosed. Therefore, the increasing need for cancer treatment is expected to boost the demand for the global oncology cancer drugs market during the forecast period.

Market Dynamics

Market Growth Drivers

The growth of the oncology drug market is attributed to the population of Russia ages, and the incidence of cancer is expected to increase. The surge in the incidence of cancer across the country, the increase in the aging population (16% of Russia’s total population is above 65 age), and, the surge in the number of pipeline drugs and untapped potential in emerging geographies create new opportunities in the market. Due to the availability of new and innovative treatments, the oncology drug market is expected to benefit from the introduction of new and innovative treatments, including targeted therapies and immunotherapies. Moreover, the adoption of personalized medicine approaches personalized medicine, which involves tailoring treatment to the individual characteristics of each patient, is expected to play a significant role in the growth of the oncology drug market in Russia.

Market Restraints

Adverse effects related to the usage of cancer drugs hinder market growth. negatively influencing the growth of the market. and biological data to identify potential drug candidates with higher success rates than human analysis.

Competitive Landscape

Key Players

Key players in the oncology market include

Roche
Bristol-Myers Squibb
Veropharm (Abbott)
MSD
Sanofi
Novartis
Pfizer
AstraZeneca
Eli Lilly
Takeda
Bayer
Sandoz

Notable Recent Deals

September 2021: Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, announces that it has signed a license agreement with the Swiss-based FarmaMondo Group for the commercialization of Paclical® (Apealea®) in Russia and the Commonwealth of Independent States.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario of Russia Oncology Drugs Services

In 2011, 5 targeted cancer therapies were covered in the essential drug list (Bevacizumab, Rituximab, Trastuzumab, Imatinib and Bortezomib). In 2012, an additional 8 branded cancer drugs were added to the list, expanding the coverage of targeted cancer therapies to 13 products. The price change trend for selected analogs shows some products covered at the same price, while for others price was reduced by 5-10%. For example, one of the covered monoclonal antibodies’ prices did not change during 2011 and 2012, while prices for a proteasome inhibitor and a tyrosine kinase inhibitor were lowered by 6% and 10%, respectively.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Drugs Market Segmentation

By Drug class

Cytotoxic drugs
- Alkylating agents
- Antimetabolites
- Others
Targeted drugs
- Monoclonal antibodies
- Others
Hormonal drugs
Others

By Therapy

Chemotherapy
Targeted therapy
Immunotherapy

By Indication

Lung cancer
Stomach cancer
Colorectal cancer
Breast cancer
Prostate cancer
Others

By Dosage form

Solid
- Tablets
- Capsules
Liquid
Injectable
- Prefilled syringes
- Others

By Distribution channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
?Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.